Consortium organization
The organizational structure of Lifelong VISION is designed to promote (i) transparent and collaborative decision-making at all levels, (ii) efficient progress monitoring and reporting, (ii) fruitful interactions with external experts and stakeholders, and (iv) optimal embedding at the participating institutes.
learn moreConsortium organization
The organizational structure of Lifelong VISION is designed to promote (i) transparent and collaborative decision-making at all levels, (ii) efficient progress monitoring and reporting, (ii) fruitful interactions with external experts and stakeholders, and (iv) optimal embedding at the participating institutes.
The organizational structure consists of the following Consortium Bodies:
- Executive Board
- Coordinator
- Project Support Office
Furthermore, the following advisory boards and councils shall exist:
- Scientific Advisory Board (SAB)
- Institutional Board (IB)
The people involved
The program is organized in pillars and platforms. Each of those has a page the team members:
- Pillar 1: Gene-based therapy
- Pillar 2: Pathway-based therapy
- Pillar 3: Cell-based therapy
- Platform A: Model systems
- Platform B: Patient profiling
For an overview of everyone involved please visit our team page.
Gene-based therapy Pillar 1
To design and refine truly personalized, innovative and effective treatments for visually impaired individuals.
go to pagePatient profiling Platform B
A datadriven approach to define intervention-specific disease signatures.
go to pageScientific Advisory Board
Anneke den Hollander
About me
Distinguished global pharma leader with expertise in Genomics, Functional Genomics and Ophthalmology. Proven commitment to making a difference for patients, leveraging scientific excellence and translating research findings into innovations, treatments, and cures. Adept at mentoring, developing, and motivating cross-functional teams and providing strategic direction.
Areas of expertise include:
• Portfolio leadership
• Target identification and validation using genomics, functional genomics and multi-omics approaches
• Disease modeling using in vitro (hiPSC-derived cell types, organ-on-a-chip) and in vivo models
• Biomarkers for disease development, disease progression and treatment outcome
Christine Mummery
About me
Christine Mummery is Professor of Developmental Biology and heads the iPSC&OoC Hotel facility in the LUMC which she founded in 2011. She was head of the department Anatomy and Embryology from 2009-2019 and guest professor at the University of Twente from 2015-2023. She is a member of the KNAW, KHMW and is a laureate or the European Research Council (Advanced and Proof-of-Concept grants). In the LUMC she co-chairs the Theme RegMedTO and PI in the Novo Nordisk Foundation Stem Cell Center (reNEW), a collaboration between the University of Copenhagen and Murdoch Children’s Hospital in Melbourne. She has been awarded a number of prizes include the Fondation Lefoulon-Delalande-Institut de France prize for cardiovascular physiology (2021) and the Public Service Award (2023) of the International Society of Stem Cell Research (ISSCR). She was ISSCR president 2020-2021. She wrote a lay guide to stem cells (“Stem Cells: Scientific Facts and Fiction”; Elsevier 3rd edition 2018) which is widely used by students, patients, ethicists and lawyers. She has serves on panels of ZonMW, the ERC, British Heart Foundation, Medical Research Council (UK), and the California Institute of Regenerative Medicine. She was co-founder and first chair of the European Organ on Chip Society. She is currently chair of the board of hDMT.
Kapil Bharti
Senior Investigator at NEI and Scientific Director of the Intramural Research Program at the National Eye Institute
read more
Marius Ueffing
Professor, Dr. rer.nat.
Director of the Institute for Ophthalmic Research
Head of the Division of Molecular Biology of Retinal Degenerations
Head of the Core Facility for Medical Bioanalytics
University Medical Center Tuebingen
read moreMarius Ueffing
About me
Marius Ueffing is the Director of the Institute for Ophthalmic Research and Co-Chair of the Centre for Ophthalmology at the University Medical Center in Tuebingen, one of the largest centers for ophthalmology in Europe. He directs the Medical Bioanalytics Core Facility a core facility of the medical faculty in Tübingen and acts as a Member of the Board of QBiC, the Quantitative Biology Center of the University of Tuebingen. His research combines cellular and molecular physiology with genome and proteome analysis to analyse the impact of genetic and environmental factors on human health on a systemic level. Focus of the lab is neurodegeneration in the retina with specific emphasis on the molecular mechanisms of disease towards development of targeted therapy.
Core expertise: Experimental ophthalmology; medical genetics; bioanalytics; systems biology, signal transduction, proteomics, neurobiology
Reinier Schlingemann
Professor of Ophthalmology and Vascular Diseases of the Macula
University of Amsterdam
read moreReinier Schlingemann
About me
Focus of research
- The role of angiogenic and anti-angiogenic factors in ocular angiogenesis, particularly in AMD and diabetic retinopathy
- The cellular mechanisms underlying loss of the blood-retinal barrier in diabetic retinopathy
- Identification of new genes and mechanisms of angiogenesis
- The role of complement activation and the proteasome in retinal pigment epithelium in the early stages of age-related macular degeneration
- Prospective clinical trials on the use of anti-angiogenic therapy in AMD, diabetic retinopathy and retinal vein occlusions